MedTrace Logo

Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors

NCT06054932 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-09-26

No results posted yet for this study

Summary

This is an open-labeled, single-center phase I study in patients with incurable advanced solid tumors, who failed with all previous standard therapy. The aim is to observe and evaluate the safety, tolerability, and immunogenicity of LK101 injection.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

LK101 injection

LK101 administrated Q2W as the prime dose, and Q3W in the boost phase

DRUG

LK101 injection

LK101 administrated QW as the prime dose, and Q3W in the boost phase

Sponsors & Collaborators

  • Beijing Likang Life Science and Tech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-05
Primary Completion
2025-12-30
Completion
2026-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06054932 on ClinicalTrials.gov